Shigeaki Sunada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shigeaki Sunada has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Yoshio Miki
Department of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Japan
4 shared publications Doudou Zhang
Department of Molecular Genetics, Medical Research Institute Tokyo Medical and Dental University Tokyo Japan
3 shared publicationsQianqian Guo
Department of Molecular Genetics, Medical Research Institute Tokyo Medical and Dental University Tokyo Japan
3 shared publications- Takamitsu A. Kato
Department of Environmental and Radiological Health Sciences, Colorado State University
3 shared publications Yoshio Miki
Research and Development Center for Precision Medicine University of Tsukuba Ibaraki Japan
3 shared publicationsAkira Fujimori
2 shared publications
Latest Publications
- 27 May 2025
- Published by Springer Nature
- Vol. 2933, 113-117
Chemical-Induced DNA Damage Identification by High-Throughput Detection of DNA Double-Strand Break
Numerous chemicals cause diverse types of DNA damage in cells. However, the failure of DNA repair associated with the formation of these lesions converts the diverse forms of DNA damage into the more severe form of damage, the DNA double-strand break (DSB). The DSB is also considered an early factor in the carcinogenic process. Therefore, analytical methods for detecting DSBs can contribute to the detection of carcinogenic chemicals. γH2AX has been widely used as a highly sensitive marker for DSB, and analytical methods using flow cytometry have excellent quantitative properties. I further attempted to simplify and expedite the method while maintaining its quantitative performance and established a high-throughput DSB quantification method. In this section, I present a simple method for evaluating the DNA damage potential of chemicals in terms of DSB formation.
- 27 May 2025
- Published by Springer Nature
- Vol. 2933, 113-117
Chemical-Induced DNA Damage Identification by High-Throughput Detection of DNA Double-Strand Break
Numerous chemicals cause diverse types of DNA damage in cells. However, the failure of DNA repair associated with the formation of these lesions converts the diverse forms of DNA damage into the more severe form of damage, the DNA double-strand break (DSB). The DSB is also considered an early factor in the carcinogenic process. Therefore, analytical methods for detecting DSBs can contribute to the detection of carcinogenic chemicals. γH2AX has been widely used as a highly sensitive marker for DSB, and analytical methods using flow cytometry have excellent quantitative properties. I further attempted to simplify and expedite the method while maintaining its quantitative performance and established a high-throughput DSB quantification method. In this section, I present a simple method for evaluating the DNA damage potential of chemicals in terms of DSB formation.
- Open Access
- 15 April 2025
- Published by Wiley in Cancer Science
- Vol. 116 (7) , 1952-1962
Steroid‐Modulated Transcription Synergistically Forms DNA Double‐Strand Breaks With Topoisomerase II Inhibitor
The synergistic effects of drug combinations have emerged as a promising approach for achieving efficient cancer treatment. Through our exploration of drug combinations, we found that medroxyprogesterone acetate (MPA), a steroid, induced a synergistic antitumor effect in combination with the topoisomerase II inhibitor etoposide (ETP). In this study, we investigated the mechanisms underlying this synergistic effect for potential clinical applications. To elucidate the relevant mechanisms, we performed a cell viability assay, cell cycle analysis, DNA repair assays, detection of DNA double‐strand breaks (DSBs) and the nuclear localization of topoisomerase II (Top2), and genome‐wide detection of DSBs. MPA synergistically increased ETP‐induced DSBs, resulting in cell cycle arrest in the G2/M phase. Interestingly, this effect was not due to the inhibition of DSB repair but to a specific increase in the Top2‐DNA covalent complex formed by ETP. A genome‐wide search for DSB locations revealed that DSB formation was promoted near promoter regions, suggesting the involvement of MPA transcriptional modulation in this mechanism. We also found that various steroids promoted DSB formation when combined with ETP, strongly supporting our synergistic model. Therefore, this synergistic effect is based on an innovative mechanism that differs from conventional strategies targeting the DNA damage response and is expected to contribute toward novel therapeutic options.
- 15 April 2025
- Published by Wiley in Cancer Science
- Vol. 116 (7) , 1952-1962
Open AccessSteroid‐Modulated Transcription Synergistically Forms DNA Double‐Strand Breaks With Topoisomerase II Inhibitor
The synergistic effects of drug combinations have emerged as a promising approach for achieving efficient cancer treatment. Through our exploration of drug combinations, we found that medroxyprogesterone acetate (MPA), a steroid, induced a synergistic antitumor effect in combination with the topoisomerase II inhibitor etoposide (ETP). In this study, we investigated the mechanisms underlying this synergistic effect for potential clinical applications. To elucidate the relevant mechanisms, we performed a cell viability assay, cell cycle analysis, DNA repair assays, detection of DNA double‐strand breaks (DSBs) and the nuclear localization of topoisomerase II (Top2), and genome‐wide detection of DSBs. MPA synergistically increased ETP‐induced DSBs, resulting in cell cycle arrest in the G2/M phase. Interestingly, this effect was not due to the inhibition of DSB repair but to a specific increase in the Top2‐DNA covalent complex formed by ETP. A genome‐wide search for DSB locations revealed that DSB formation was promoted near promoter regions, suggesting the involvement of MPA transcriptional modulation in this mechanism. We also found that various steroids promoted DSB formation when combined with ETP, strongly supporting our synergistic model. Therefore, this synergistic effect is based on an innovative mechanism that differs from conventional strategies targeting the DNA damage response and is expected to contribute toward novel therapeutic options.
- Open Access
- 2 January 2025
- Published by Springer Nature in EMBO Reports
- Vol. 26 (3) , 635-655
Nuclear PD-L1 triggers tumour-associated inflammation upon DNA damage
Immune checkpoint inhibitors against PD-1/PD-L1 are highly effective in immunologically hot tumours such as triple-negative breast cancer, wherein constitutive DNA damage promotes inflammation, while inducing PD-L1 expression to avoid attack by cytotoxic T cells. However, whether and how PD-L1 regulates the DNA damage response and inflammation remains unclear. Here, we show that nuclear PD-L1 activates the ATR-Chk1 pathway and induces proinflammatory chemocytokines upon genotoxic stress. PD-L1 interacts with ATR and is essential for Chk1 activation and chromatin binding. cGAS-STING and NF-κB activation in the late phase of the DNA damage response is inhibited by PD-L1 deletion or by inhibitors of ATR and Chk1. Consequently, the induction of proinflammatory chemocytokines at this stage is inhibited by deletion of PD-L1, but restored by the ATR activator Garcinone C. Inhibition of nuclear localisation by PD-L1 mutations or the HDAC2 inhibitor Santacruzamate A inhibits chemocytokine induction. Conversely, the p300 inhibitor C646, which accelerates PD-L1 nuclear localisation, promotes chemocytokine induction. These findings suggest that nuclear PD-L1 strengthens the properties of hot tumours and contributes to shaping the tumour microenvironment.
- 2 January 2025
- Published by Springer Nature in EMBO Reports
- Vol. 26 (3) , 635-655
Open AccessNuclear PD-L1 triggers tumour-associated inflammation upon DNA damage
Immune checkpoint inhibitors against PD-1/PD-L1 are highly effective in immunologically hot tumours such as triple-negative breast cancer, wherein constitutive DNA damage promotes inflammation, while inducing PD-L1 expression to avoid attack by cytotoxic T cells. However, whether and how PD-L1 regulates the DNA damage response and inflammation remains unclear. Here, we show that nuclear PD-L1 activates the ATR-Chk1 pathway and induces proinflammatory chemocytokines upon genotoxic stress. PD-L1 interacts with ATR and is essential for Chk1 activation and chromatin binding. cGAS-STING and NF-κB activation in the late phase of the DNA damage response is inhibited by PD-L1 deletion or by inhibitors of ATR and Chk1. Consequently, the induction of proinflammatory chemocytokines at this stage is inhibited by deletion of PD-L1, but restored by the ATR activator Garcinone C. Inhibition of nuclear localisation by PD-L1 mutations or the HDAC2 inhibitor Santacruzamate A inhibits chemocytokine induction. Conversely, the p300 inhibitor C646, which accelerates PD-L1 nuclear localisation, promotes chemocytokine induction. These findings suggest that nuclear PD-L1 strengthens the properties of hot tumours and contributes to shaping the tumour microenvironment.
- 20 September 2023
- Published by Springer Nature in Journal of Human Genetics
- Vol. 68 (12) , 849-857
Functional evaluation of BRCA1/2 variants of unknown significance with homologous recombination assay and integrative in silico prediction model
Numerous variants of unknown significance (VUSs) exist in hereditary breast and ovarian cancers. Although multiple methods have been developed to assess the significance of BRCA1/2 variants, functional discrepancies among these approaches remain. Therefore, a comprehensive functional evaluation system for these variants should be established. We performed conventional homologous recombination (HR) assays for 50 BRCA1 and 108 BRCA2 VUSs and complementarily predicted VUSs using a statistical logistic regression prediction model that integrated six in silico functional prediction tools. BRCA1/2 VUSs were classified according to the results of the integrative in vitro and in silico analyses. Using HR assays, we identified 10 BRCA1 and 4 BRCA2 VUSs as low-functional pathogenic variants. For in silico prediction, the statistical prediction model showed high accuracy for both BRCA1 and BRCA2 compared with each in silico prediction tool individually and predicted nine BRCA1 and seven BRCA2 variants to be pathogenic. Integrative functional evaluation in this study and the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines strongly suggested that seven BRCA1 variants (p.Glu272Gly, p.Lys1095Glu, p.Val1653Leu, p.Thr1681Pro, p.Phe1761Val, p.Thr1773Ile, and p.Gly1803Ser) and four BRCA2 variants (p.Trp31Gly, p.Ser2616Phe, p.Tyr2660Cys, and p.Leu2792Arg) were pathogenic. This study demonstrates that integrative evaluation using conventional HR assays and optimized in silico prediction comprehensively classified the significance of BRCA VUSs for future clinical applications.
- 20 September 2023
- Published by Springer Nature in Journal of Human Genetics
- Vol. 68 (12) , 849-857
Functional evaluation of BRCA1/2 variants of unknown significance with homologous recombination assay and integrative in silico prediction model
Numerous variants of unknown significance (VUSs) exist in hereditary breast and ovarian cancers. Although multiple methods have been developed to assess the significance of BRCA1/2 variants, functional discrepancies among these approaches remain. Therefore, a comprehensive functional evaluation system for these variants should be established. We performed conventional homologous recombination (HR) assays for 50 BRCA1 and 108 BRCA2 VUSs and complementarily predicted VUSs using a statistical logistic regression prediction model that integrated six in silico functional prediction tools. BRCA1/2 VUSs were classified according to the results of the integrative in vitro and in silico analyses. Using HR assays, we identified 10 BRCA1 and 4 BRCA2 VUSs as low-functional pathogenic variants. For in silico prediction, the statistical prediction model showed high accuracy for both BRCA1 and BRCA2 compared with each in silico prediction tool individually and predicted nine BRCA1 and seven BRCA2 variants to be pathogenic. Integrative functional evaluation in this study and the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines strongly suggested that seven BRCA1 variants (p.Glu272Gly, p.Lys1095Glu, p.Val1653Leu, p.Thr1681Pro, p.Phe1761Val, p.Thr1773Ile, and p.Gly1803Ser) and four BRCA2 variants (p.Trp31Gly, p.Ser2616Phe, p.Tyr2660Cys, and p.Leu2792Arg) were pathogenic. This study demonstrates that integrative evaluation using conventional HR assays and optimized in silico prediction comprehensively classified the significance of BRCA VUSs for future clinical applications.
- Open Access
- 30 November 2022
- Published by Wiley in Cancer Science
- Vol. 114 (3) , 1108-1117
Discovery of novel DNA‐damaging agents through phenotypic screening for DNA double‐strand break
DNA double‐strand breaks (DSBs) seriously damage DNA and promote genomic instability that can lead to cell death. They are the source of conditions such as carcinogenesis and aging, but also have important applications in cancer therapy. Therefore, rapid detection and quantification of DSBs in cells are necessary for identifying carcinogenic and anticancer factors. In this study, we detected DSBs using a flow cytometry‐based high‐throughput method to analyze γH2AX intensity. We screened a chemical library containing 9600 compounds and detected multiple DNA‐damaging compounds, although we could not identify mechanisms of action through this procedure. Thus, we also profiled a representative compound with the highest DSB potential, DNA‐damaging agent‐1 (DDA‐1), using a bioinformatics‐based method we termed “molecular profiling.” Prediction and verification analysis revealed DDA‐1 as a potential inhibitor of topoisomerase IIα, different from known inhibitors such as etoposide and doxorubicin. Additional investigation of DDA‐1 analogs and xenograft models suggested that DDA‐1 is a potential anticancer drug. In conclusion, our findings established that combining high‐throughput DSB detection and molecular profiling to undertake phenotypic analysis is a viable method for efficient identification of novel DNA‐damaging compounds for clinical applications.
- 30 November 2022
- Published by Wiley in Cancer Science
- Vol. 114 (3) , 1108-1117
Open AccessDiscovery of novel DNA‐damaging agents through phenotypic screening for DNA double‐strand break
DNA double‐strand breaks (DSBs) seriously damage DNA and promote genomic instability that can lead to cell death. They are the source of conditions such as carcinogenesis and aging, but also have important applications in cancer therapy. Therefore, rapid detection and quantification of DSBs in cells are necessary for identifying carcinogenic and anticancer factors. In this study, we detected DSBs using a flow cytometry‐based high‐throughput method to analyze γH2AX intensity. We screened a chemical library containing 9600 compounds and detected multiple DNA‐damaging compounds, although we could not identify mechanisms of action through this procedure. Thus, we also profiled a representative compound with the highest DSB potential, DNA‐damaging agent‐1 (DDA‐1), using a bioinformatics‐based method we termed “molecular profiling.” Prediction and verification analysis revealed DDA‐1 as a potential inhibitor of topoisomerase IIα, different from known inhibitors such as etoposide and doxorubicin. Additional investigation of DDA‐1 analogs and xenograft models suggested that DDA‐1 is a potential anticancer drug. In conclusion, our findings established that combining high‐throughput DSB detection and molecular profiling to undertake phenotypic analysis is a viable method for efficient identification of novel DNA‐damaging compounds for clinical applications.
- 21 October 2021
- Published by Springer Nature
- p. 281-292
PARP Inhibitors: Mechanism of Action
- Open Access
- 1 April 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 550, 56-61
CDK1 inhibitor controls G2/M phase transition and reverses DNA damage sensitivity
- 1 April 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 550, 56-61
Open AccessCDK1 inhibitor controls G2/M phase transition and reverses DNA damage sensitivity
- 1 September 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 150, 253-261
A multimodal treatment of carbon ions irradiation, miRNA-34 and mTOR inhibitor specifically control high-grade chondrosarcoma cancer stem cells
- 1 September 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 150, 253-261
A multimodal treatment of carbon ions irradiation, miRNA-34 and mTOR inhibitor specifically control high-grade chondrosarcoma cancer stem cells